截至2025年7月22日15时，昊帆生物股价报55.37元，较前一交易日下跌0.74%。当日成交量为28927手，成交金额达1.61亿元。
昊帆生物所属板块包括生物制品、CRO等领域。公司主营业务涵盖多肽合成试剂的研发与生产，产品应用于医药研发及生产环节。
世界卫生组织计划于2025年9月发布基于GLP-1疗法的成人肥胖症治疗新指南。该指南将明确GLP-1受体激动剂的临床应用标准，标志着世卫组织首次正式推荐使用减肥药物治疗肥胖症。在相关产业链中，昊帆生物被列为值得关注的企业之一。
2025年7月22日，昊帆生物主力资金净流入74.15万元。
风险提示：以上内容仅供参考，不构成投资建议。市场有风险，投资需谨慎。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.